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rheumatoid arthritis: comparison with participants
from the Multi-Ethnic Study of Atherosclerosis
Cecilia P Chung1,8, Jon T Giles2, Richard A Kronmal4, Wendy S Post3,5, Allan C Gelber1,5, Michelle Petri1,
Moyses Szklo5, Robert Detrano6, Matthew J Budoff7, Roger S Blumenthal3, Pamela Ouyang3, David Bush3
and Joan M Bathon2*Abstract
Introduction: In cross-sectional studies, patients with rheumatoid arthritis (RA) have higher coronary artery calcium
(CAC) than controls. However, their rate of progression of CAC and the predictors of CAC progression have
heretofore remained unknown.
Methods: Incidence and progression of CAC were compared in 155 patients with RA and 835 control participants.
The association of demographic characteristics, traditional cardiovascular risk factors, RA disease characteristics and
selected inflammatory markers with incidence and progression of CAC were evaluated.
Results: The incidence rate of newly detected CAC was 8.2/100 person-years in RA and 7.3/100 person-years in
non-RA control subjects [IRR 1.1 (0.7-1.8)]. RA patients who developed newly detectable CAC were older (59±7 vs.
55±6 years old, p=0.03), had higher triglyceride levels (137±86 vs. 97±60 mg/dL, p=0.03), and higher systolic blood
pressure (129±17 vs. 117±15 mm Hg, p=0.01) compared to those who did not develop incident CAC. Differences in
blood pressure and triglyceride levels remained significant after adjustment for age (p<=0.05). RA patients with any
CAC at baseline had a median rate of yearly progression of 21 (7–62) compared to 21 (5–70) Agatston units in
controls. No statistical differences between RA progressors and RA non-progressors were observed for inflammatory
markers or for RA disease characteristics.
Conclusions: The incidence and progression of CAC did not differ between RA and non-RA participants. In patients
with RA, incident CAC was associated with older age, higher triglyceride levels, and higher blood pressure, but not
with inflammatory markers or RA disease characteristics.Introduction
Patients with rheumatoid arthritis (RA) die prematurely
[1] and the leading cause of death is coronary artery di-
sease [2-7].
High resolution computed tomography is a non-
invasive technique that allows the identification and
quantification of coronary artery calcium (CAC). Prior
studies have shown that CAC scores correlate with the
presence and extent of coronary plaque [8] and its pre-
sence is associated with a higher risk of coronary heart
disease [9-12].* Correspondence: jmb2311@columbia.edu
2Division of Rheumatology, Columbia University, New York, NY, USA
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reproduction in any medium, provided the orOur previous research showed that patients with RA
have higher CAC scores than control subjects [13,14].
These studies indicated that there was an association
between higher CAC scores with sedimentation rate,
smoking and a composite score of disease activity and
severity. However, these associations were established in
cross-sectional analyses; thus, they did not allow assess-
ment of temporal sequence, which would further sup-
port causality.
The rate and predictors of progression of coronary
atherosclerosis in RA are unknown. Therefore, we set
out to test the hypotheses that: (1) subclinical coronary
artery atherosclerosis, as measured by CAC, progresses
more rapidly in patients with RA than in controls fromLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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sures of disease activity, disease damage, inflammation
and traditional cardiovascular risk factors are indepen-
dent predictors of higher incident rates and progression
of coronary artery atherosclerosis.
Methods
This is a prospective study of patients with RA and
control subjects from two cohorts that followed similar
protocols, the Evaluation of Subclinical Cardiovascular
Disease and Predictors of Events in Rheumatoid Arthri-
tis (ESCAPE RA) cohort [14-16] and the Multi-Ethnic
Study of Atherosclerosis (MESA) [17]. The study design
is summarized in Figure 1.
Cohorts
The ESCAPE RA cohort was assembled to study the
prevalence and progression of atherosclerosis and to
identify risk factors for prevalent and progressive sub-
clinical cardiovascular disease in patients with RA. De-
tails of this cohort have been described before [14]. In
brief, the cohort was assembled in the greater Baltimore
area. Eligibility criteria included fulfillment of the 1987Figure 1 Study design and disposition of participants. f/u, follow-up; pAmerican College of Rheumatology classification criteria
for RA [18] and age 45 through 84 years. Major exclu-
sion criteria were: (1) self-reported history of physician-
diagnosed myocardial infarction, heart failure, coronary
artery revascularization, peripheral arterial disease, im-
planted pacemaker or defibrillator devices and current
atrial fibrillation; (2) weight exceeding 300 pounds; and
(3) computerized tomographic (CT) scan of the chest
within six months prior to study enrollment. A total of
197 patients were enrolled in this study from October
2004 through May 2006. Of these, 195 patients com-
pleted the initial evaluation, including assessment for the
presence of CAC at baseline. Further, 155 patients had a
three-year follow-up visit including a second CAC mea-
surement. These 155 patients constituted the RA study
sample for the present analyses.
Control subjects were part of the MESA (Multi-Ethnic
Study of Atherosclerosis), a population-based cohort as-
sembled in 2000 to 2002 to study the prevalence, risk
factors and progression of subclinical atherosclerosis.
Details of the study design have been published [17]. In
brief, individuals were enrolled if they were 45 through
84 years of age and did not report a past history of at/yr, patient-years; RA, rheumatoid arthritis.
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and thirty-five participants from the Baltimore Field
Center who completed a follow-up evaluation, had CT
evaluation at baseline and follow-up and were not taking
any disease modifying anti-rheumatic drug, constituted
the comparison group for these analyses. The study was
approved by the Johns Hopkins Hospital Institutional
Review Board and MESA, with all participants providing
informed consent prior to enrollment.
Study outcomes
CAC was ascertained with the use of cardiac CT using a
multidetector row computed tomography (MDCT) sys-
tem [19]. Scans were transmitted electronically to the
MESA CT reading center where calcium scores were
quantified using the methods described by Agatston
[20]. Scoring of scans was blinded to the group alloca-
tion (RA and control).
Patients with RA had their second CAC measurement
after an average of 3.2 (range: 2.2 to 4.2) years. In MESA
participants, the second CAC scan was obtained on 391
participants of the MESA cohort during visit 2 and on
444 during visit 3. The mean follow-up time to repeat
scan in controls was 2.3 (range: 0.9 to 4.6) years.
Given that CAC scores are highly skewed and that
about half of the participants had a calcium score of zero
at baseline, two pre-specified outcomes for subgroup
analyses were defined following the design previously
described by Kronmal et al. [21]:
– Incidence of CAC: all participants with a CAC score
of zero at baseline were included in the analysis of
incident CAC. The incident case definition required
progression to a positive calcium score (≥1) over time.
– Progression of CAC: restricted to those participants
with any detectable CAC at baseline.
Study covariates
Demographic and clinical characteristics, cardiovascular
risk factors, serum/plasma concentrations of inflamma-
tory markers in RA patients and controls were collected
following similar protocols.
Clinical evaluation of cardiovascular risk factors
– Blood pressure (BP) was measured three times while
individuals were sitting. The average of the last two
measurements was used in the analysis.
Hypertension was defined by systolic BP ≥140 mmHg,
diastolic BP ≥90 mm Hg, or antihypertensive
drug use.
– Diabetes was defined as a fasting glucose ≥126 mg/dL
or use of anti-diabetic medications.
– Smoking status was ascertained by self-report.Laboratory methods
Fasting sera and plasma were separated by centrifugation
and stored at −70°C. Total and high density lipoprotein
(HDL) cholesterol, triglyceride, C-reactive protein (CRP),
IL-6 and fibrinogen were measured at the MESA core
laboratory, the Laboratory for Clinical Biochemistry Re-
search (University of Vermont). In patients with RA,
anti-cyclic citrullinated peptide (anti-CCP) antibodies
and rheumatoid factor (RF) were measured as previously
described [14]. Low density lipoprotein (LDL) choles-
terol was calculated using the Friedewald equation [19].
RA disease characteristics
The number of tender and swollen joints was ascertained
and disease activity (DAS28) calculated using the 28-joint
count and CRP [22]. Radiographic damage was quantified
by the Sharp score and functional capacity was determined
by the Health Assessment Questionnaire (HAQ) [23].
Anti-CCP antibody and RF greater than or equal to
60 and 40 units, respectively, met the definition of
seropositivity.
The presence of HLA associated RA susceptibility
alleles (the so-called ‘shared epitope’) was defined as
the presence of alleles QKRAA, QRRAA, QRAAA and
RRRAA at positions 70 to 74 of Exon 2 of HLA-DRB1
using Allele SEQR HLA-DRB1 SBT kits (Abbott Molecu-
lar, Inc., Des Plaines, IL, USA). Radiographs of the hands
and feet were scored using the Sharp-van der Heijde
method [24] by a single, trained radiologist. As previously
described, there were five subjects with incomplete radio-
graphic assessments, in whom the scores were imputed
from the available data [25].
Statistical methods
For all variables, means and standard deviations sum-
marize normally distributed data. For variables with
skewed distribution, the data are presented as medians
and interquartile ranges (IQRs). Clinical and laboratory
data ascertained longitudinally are expressed as baseline
and as average over follow-up. Categorical variables are
presented as proportions. Differences between continu-
ous variables were tested using the Wilcoxon-rank sum
test or the t-test and between categorical variables, with
the Chi-squared or Fisher’s exact test.
The incidence rate of CAC in RA patients and control
subjects is presented as person-years and compared
using Poisson regression. Multivariable regressions were
modeled to examine if any differences were independent
of traditional cardiovascular risk factors, using backward
elimination by blocks.
Yearly progression rate was compared among RA pa-
tients and controls with CAC >0 at baseline. Robust linear
regressions were modeled to examine whether progression
was greater in RA patients than in controls and if any
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traditional cardiovascular risk factors.
The associations between traditional risk factors and
progression of CAC were explored and heterogeneity
was tested between ‘caseness’ and selected variables with
multiplicative interaction models.
Finally, among RA patients, the association between
traditional cardiovascular risk factors and RA disease
characteristics with progression of CAC was also ex-
plored. Variables included disease activity, radiogra-
phic damage, medications and markers of inflammation.
Poisson regression or robust linear regression was used, as
appropriate.
All statistical tests were calculated using a 5% two-
sided significance level using STATA/IC 11.0 (StataCorp,
College Station, Texas, USA).
Results
Table 1 presents the clinical characteristics at baseline of
the 155 RA patients and the 835 MESA participants.Table 1 Baseline characteristics according to RA status
Characteristic RA
Number = 1
Demographics
Age, years 59.2 ± 8.3
Female; n (%) 97 (63%)
Caucasian race; n (%) 136 (88%)
Education; n (%) 122 (79%)
Some college or higher
Cardiovascular Risk Factors
Diabetes; number (%) 11 (7%)
Hypertension (%) 87 (56%)
Systolic BP, mm Hg 126 ± 17
Diastolic BP, mm Hg 75 ± 9
Dyslipidemia
Total cholesterol, mg/dL 198 ± 40
LDL cholesterol, mg/dL 117 ± 32
HDL cholesterol, mg/dL 56 ± 20
Triglycerides, mg/dL 126 ± 98
Cigarette smoking
Current; number(%) 15 (10%)
Serum inflammatory markers
CRP, mg/L; median (IQR) 2.3 (1.1, 6.7
IL-6, pg/mL; median (IQR) 3.6 (1.6, 7.5
Fibrinogen, mg/dL; median (IQR) 335 (278, 41
Prevalence of CAC 82 (52.9%)
Unadjusted CAC score (Agatston Units) 3.1 (0, 135.1
BP, blood pressure; CAC, coronary artery calcium; CRP, C-reactive protein; HDL, high
rheumatoid arthritis.Patients with RA were, on average, four years younger
than control subjects. There were higher proportions of
women, Caucasians and individuals who completed a
12th grade education in the RA group than in the con-
trol group (each P <0.05).
Patients and controls had a similar prevalence of
hypertension, but diabetes at baseline was more pre-
valent in controls than in RA patients. Average HDL
cholesterol was higher in RA participants than in
controls, but there were no statistically significant
differences in average LDL cholesterol or triglyceride
levels. Not surprisingly, patients with RA had higher
concentrations of IL-6, on average (P <0.001). How-
ever, RA patients did not have higher concentra-
tions of CRP or fibrinogen, on average, compared to
controls.
Patients with RA had a median disease duration of
nine years and a mean DAS28 of 3.7 ± 1.1. Seventy
percent had the shared epitope, 65% were seropositive
for RF and 77% seropositive for anti-CCP antibodies.Controls P
55 Number = 835
62.8 ± 10.0 <0.001
437 (52%) 0.019
425 (51%) <0.001
580 (70%) 0.035
137 (16%) 0.003
465 (56%) 0.92
126 ± 20 0.72
71 ± 10 <0.001
192 ± 35 0.10
118 ± 31 0.74
51 ± 14 <0.001
117 ± 72 0.20
103 (12%) 0.32
) 2.2 (1.0, 4.6) 0.18
) 1.3 (0.8, 1.91) <0.001
6) 339 (294, 387) 0.79
454 (54.3%) 0.79
) 6.4 (0, 119.6) 0.68
density lipoprotein; IQR, interquartile range; LDL, low density lipoprotein; RA,
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and the median HAQ score was 0 (0 to 1).
The median baseline CAC scores were not statistically
significantly different between the RA and control
groups (median (IQR): 3.1 (0, 135.1) and 6.4 (0, 119.6)
Agatston units, respectively, P = 0.68). However, in an
analysis restricted to participants with baseline CAC
scores >0 and adjusted for differences in cardiovascular
disease (CVD) risk factors, baseline adjusted CAC scores
were higher in patients with RA than control subjects
(median (IQR): 173.6 (133.0 to 187.9) and 116.1 (88.5 to
145.7) Agatston units, respectively), (β = 52.3, P = 0.02).
A sensitivity analysis in which RA (n = 86) and control
(n = 86) participants were matched 1:1 for age, sex,
race, diabetes, smoking and dyslipidemia demonstra-
ted comparable findings. In these analyses, baseline
prevalences of CAC in RA versus controls were 52.3%
and 46.5%, respectively, P = 0.4; in those with base-
line CAC scores >0, median CAC scores were (median
(IQR)) 135 (21, 472) and 115 (27, 362) in RA and controls,
respectively.Incident CAC
Table 2 presents the incidence rates of detectable CAC.
Of the 73 patients with RA and a CAC score of zero at
baseline, 20 (27%) developed detectable CAC during an
average of 3.3 ± 0.3 years of follow-up, resulting in an
incidence rate of 8.2 per 100 person-years. In the control
group, there were 381 participants free of CAC at base-
line. Among those, 65 (17%) developed detectable CAC
over an average of 2.4 ± 0.9 years of follow-up, resulting
in an incidence rate of 7.3 per 100 person-years.
When both incidence rates were compared, the un-
adjusted incidence rate ratio (IRR) was 1.14 (95% CI
0.73 to 1.75). This result did not change substantially
after adjustment for demographic variables and trad-
itional cardiovascular risk factors. A sensitivity analysis,Table 2 Incidence rate of CAC (among participants with
no CAC at baseline)
RA Controls
(Number = 73) (Number = 381)
Incident CAC, number 20 65
Person-year 243 895
Incidence rate (100 person/year) 8.2 7.3
Unadjusted IRR 1.14 (0.73, 1.75)
IRR - Model 1a 1.28 (0.83–1.98)
IRR - Model 2b 1.02 (0.63, 1.65)
IRR - Model 3c 1.11 (0.66, 1.88)
aAdjusted for age; badjusted for age, gender, ethnicity, smoking, dyslipidemia,
diabetes, and hypertension; cinteraction with gender (P for interaction = 0.56).
CAC, coronary artery calcium; IRR, incidence rate ratio; RA, rheumatoid arthritis.restricting controls with similar time to follow-up as RA
patients, yielded similar results (data not shown).Progression of CAC
RA patients with any detectable CAC at baseline had
a median yearly rate of progression of 21 (7 to 62)
Agatston units. Although the IQR varied slightly, the
median rate of progression was also 21 (5 to 70)
Agatston units in control subjects. As shown in Table 3,
there was no statistically significant association between
progression of calcium scores and RA after adjustment
for demographic variables and traditional cardiovascular
risk factors. Sensitivity analyses in which controls were
restricted to those who had similar time to follow-up as
the RA patients, and another in which adjusted baseline
CAC scores were entered into the mode, gave us similar
results (data not shown). In a final sensitivity analysis in
which RA patients (n = 86) were matched 1:1 to controls
(n = 86) for age, sex, race, diabetes, smoking, and
dyslipidemia, progression rates were not statistically dif-
ferent (19.3 (5.4 to 48.0) and 31.4 (4.2 to 66.5) Agatston
units for RA and controls, respectively (P = 0.5).Risk factors associated with incident coronary artery
calcium
RA patients who developed newly detectable CAC were
older (59+/-7 versus 55 ± 6 years old, P = 0.03), had
higher concentrations of triglycerides at baseline (137 ±
86 versus 97 ± 60 mg/dl, P = 0.01) and higher systolic
blood pressure (129 ± 17 versus 117 ± 15 mm Hg, P =
0.01) than those who did not develop any new coronary
calcification. The interaction analyses did not show dis-
ease status heterogeneity by age, triglycerides or systolic
blood pressure with regard to incident CAC (P values
for interaction = 0.36, 0.25, and 0.11, respectively). The
differences in triglycerides and blood pressure remained
statistically significant after adjustment for age. There
were no observed statistical differences in the concen-
tration of inflammatory markers or disease characteris-
tics at baseline or as average over follow-up among RATable 3 Yearly progression among participants with any
CAC at baseline
RA Controls
Median yearly progression
(Agatston units): median (IQR)
21 (7 to 62) 21 (5 to 70)
Coef (unadjusted) 0.5 (−8.2, 9.1)
Coef - Model 1a 2.1 (−6.5, 10.7)
Coef - Model 2b 1.4 (−7.5, 10.4)
Coef - Model 3c 4.1 (−9.0, 17.3)
aAdjusted for age; badjusted for age, gender, ethnicity, smoking, dyslipidemia,
diabetes, and hypertension; cwith gender using interaction model. CAC,
coronary artery calcium; IQR, interquartile range.
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who did not (Table 4).
Risk factors associated with progression of coronary
artery calcium
Coronary calcium scores progressed at a higher rate in
those patients with RA who were Caucasian and had
lower triglyceride concentrations (Table 5). This latter
association became of borderline significance after ad-
justment for age, sex, race, hypertension, diabetes and
smoking (P = 0.08). No other associations were seen be-
tween patient characteristics and faster rates of progres-
sion of CAC in patients with RA.
Discussion
To the best of our knowledge, this is the first study
evaluating determinants of CAC incidence and progres-
sion in patients with RA. Our main findings can be sum-
marized in three parts. First, our results indicate that
there were no statistically significant differences in rates
of incident CAC in patients and controls. Second, once
patients have any CAC, the progression is similar to the
progression seen in controls. Third, age, blood pressure
and triglyceride concentrations, but not markers of in-
flammation or measures of disease activity/damage, pre-
dicted newly identified coronary calcium in RA.
Our analysis suggesting similar progression of CAC in
patients and controls was not concordant with our pri-
mary hypothesis or with a prior study that showed grea-
ter progression of intima-media thickness (IMT) in the
common carotid of RA patients compared to controls
[26]. There are several potential explanations for this ap-
parent discordance. First, as suggested by Maradit-
Kremers et al., atherosclerosis may precede the clinical
presentation of RA [27]. Thus, given that we focused
on subclinical atherosclerosis, RA patients with prior
events, who may have contributed to an even greater
progression of CAC, had been excluded, and this could
have introduced a differential bias. Second, it is likely
that the increased CV event rate in RA patients com-
pared to controls in epidemiologic studies is explained,
at least in part, by rupture of vulnerable non-calcified
plaque.
Many potential predictors of progression were ex-
plored in our analysis. Our exploratory results indicate
that age, hypertriglyceridemia and blood pressure were
associated with incident CAC but we did not find statis-
tically significant associations with RA-specific variables.
In contrast, a recent analysis by our group indicated that
higher swollen joint counts and cumulative average CRP
predicted progression of carotid plaque in patients with
RA [28]. While both carotid ultrasound (US) and CAC
scores ascertain subclinical atherosclerosis, CAC mea-
sures only calcified plaque while carotid US measurescalcified and non-calcified plaque as well as intima
media thickness (IMT). Thus, each of these measures
provides different information. Calcified plaques are
good predictors of myocardial infarction (MI) and CVD
mortality events in the general population, but they are
more stable, and thus, less prone to rupture and cause
an event.
In contrast, carotid US measures both non-calcified
and calcified plaques. Non-calcified plaques account for
approximately three-quarters of all coronary lesions [29],
are associated with inflammation [30] and are also im-
portant predictors of cardiovascular hard events [31].
Thus, it is possible that the assessment of this type of
plaque could improve cardiovascular risk stratification
in patients with RA. This study has several strengths.
First, it compares two contemporary cohorts and data
were collected prospectively. Second, both groups were
studied following similar and rigorous protocols. Third,
it uses state of the art techniques to ascertain CAC and
to measure inflammatory markers.
Our study also has some limitations. First, although
the rate of successful follow-up was high, 20% of pa-
tients with RA either declined or could not be contacted
for their final follow-up assessment. We hypothesized
that patients who were lost to follow-up may have had
more severe disease; however, median baseline DAS and
HAQ scores were similar among patients who came
back for a second visit and those who were lost to
follow-up. Second, the average follow-up was only 3.2
years in RA patients and 2.3 years in controls and, to ac-
count for this, required estimation of average yearly pro-
gression. Longer follow-up and the evaluation of CV
events, such as acute MI and CV deaths, will be more
informative. Third, type II error might explain lack of
statistical significance in some of the subgroup analyses.
For example, a pre-study power analysis estimated that
to show a difference in CAC scores among individuals
with any coronary calcification detected at baseline
would have required a difference of 26 Agatston units
per year between RA patients and controls. In addition,
a younger cohort of patients with lower burden of cor-
onary atherosclerosis at baseline and higher RA disease
activity could have increased the likelihood of a positive
result. Fourth, the lack of association between RA and
progression of subclinical coronary atherosclerosis does
not exclude the possibility of differences in progression
of arterial calcification in other vascular beds, such as
thoracic aorta.
Conclusions
In summary, the incidence and progression of coro-
nary calcium did not differ significantly between RA
and non-RA groups. In patients with RA, higher sys-
tolic blood pressure, higher triglycerides concentrations
Table 4 Baseline characteristics associated with incident CAC (among RA patients free of CAC at baseline)
Incident CAC: yes Incident CAC: no P-value IRR (95% CI) Adjusted IRRa
(95% CI)
Demographics
Age, years 59 ± 7 55 ± 6 0.03 1.06 (1.0, 1.14) NA
Male; number (%) 5 (25%) 8 (15%) 0.32 1.65 (0.71, 3.84) 1.81 (0.79, 4.18)
Caucasian race; number (%) 19 (95%) 44 (83%) 0.18 3.03 (0.45, 20.7) 2.58 (0.39, 17.3)
Education; number (%) 16 (80%) 44 (83%) 0.76 0.86 (0.33, 2.21) 0.85 (0.32, 2.27)
Some college or higher
Cardiovascular Risk Factors
Diabetes; number (%) 1 (5%) 2 (4%) 0.81 1.14 (0.20, 6.46) 1.08 (0.21, 5.65)
Hypertension (%) 11 (55%) 21 (40%) 0.24 1.56 (0.73, 3.33) 1.42 (0.67, 3.0)
Systolic BP, mm Hg 129 ± 17 117 ± 15 0.01 1.03 (1.01, 1.05) 1.02 (1.0, 1.04)*
Diastolic BP, mm Hg 76 ± 9 72 ± 8 0.09 1.03 (0.99, 1.09) 1.05 (1.01, 1.09)*
Dyslipidemia (%)
Total cholesterol, mg/dL 201 ± 29 192 ± 41 0.40 1.0 (0.99, 1.01) 1.0 (0.99, 1.01)
LDL cholesterol, mg/dL 116 ± 20 112 ± 34 0.66 1.0 (0.99, 1.01) 1.0 (0.99, 1.01)
HDL cholesterol, mg/dL 57 ± 16 61 ± 19 0.51 0.99 (0.97, 1.01) 0.98 (0.96, 1.01)
Triglycerides, mg/dL 137 ± 86 97 ± 60 0.03 1.0004 (1.0, 1.01) 1.004 (1.0, 1.01)*
Cigarette Smoking
Current; number (%) 2 (10%) 4 (8%) 0.73 1.26 (0.36, 4.49) 0.97 (0.24, 3.94)
Serum inflammatory markers
CRP, mg/L; median (IQR) 2.1 (0.5 to 9.6) 2.1 (0.8 to 5.2) 0.74 0.96 (0.72, 1.27) 0.99 (0.75, 1.32)
IL-6, pg/mL; median (IQR) 4.0 (1.2 to 7.7) 2.3 (1.1 to 7.5) 0.45 1.12 (0.79, 1.58) 1.17 (0.83, 1.64)
Fibrinogen, mg/dL; median (IQR) 362 (260 to 473) 338 (278 to 383) 0.89 1.08 (0.33, 3.50) 1.23 (0.39, 3.94)
E-selectin, ng/mL; median (IQR) 49 (25 to 76) 45 (29 to 59) 0.90 1.0 (0.53, 1.88) 1.02 (0.58, 1.80)
s-ICAM-1, ng/mL; median (IQR) 312 (247 to 383) 275 (225 to 322) 0.12 1.60 (0.58, 4.40) 1.31 (0.47, 3.62)
Disease characteristics at baseline
Disease duration (years) 7 (4 to 14) 10 (5 to 20) 0.13 0.98 (0.94, 1.02) 0.97 (0.94, 1.01)
DAS28 3.9 ± 0.9 3.7 ± 1.0 0.44 1.19 (0.81, 1.75) 1.20 (0.81, 1.78)
HAQ 0.5 ± 0.7 0.5 ± 0.6 0.87 1.10 (0.60, 2.04) 1.12 (0.64, 1.95)
Sharp score; median (IQR) 29 (15 to 73) 44 (11 to 90) 0.93 1.0 (0.99, 1.0) 1.0 (0.99, 1.0)
Current use of MTX 10 (50%) 38 (72%) 0.08 0.52 (0.24, 1.09) 0.51 (0.25, 1.04)
Current use of biologic agents 11 (55%) 24 (45%) 0.46 1.30 (0.61, 2.79) 1.29 (0.62, 2.68)
Current use of corticosteroids 7 (35%) 19 (36%) 0.95 0.95 (0.43, 2.11) 1.02 (0.46, 2.26)
Disease characteristics, expressed as average over follow-up
DAS28 3.5 ± 1.0 3.5 ± 1.0 0.90 1.04 (0.7, 1.6) 1.06 (0.7, 1.6)
CRP, mg/L; median (IQR) 2.0 (0.9 to 6.5) 2.2 (1.2 to 6.2) 0.72 1.0 (1.0, 1.1) 1.0 (1.0, 1.1)
IL-6, pg/mL; median (IQR) 4.7 (1.5 to 20.9) 3.7 (2.0 to 11.5) 0.87 1.0 (1.0, 1.2) 1.0 (1.0, 1.1)
Fibrinogen, mg/dL; median (IQR) 358 (283 to 425) 361 (310 to 419) 0.78 1.0 (1.0, 1.0) 1.0 (1.0, 1.0)
E-selectin, ng/mL; median (IQR) 44 (34 to 61) 43 (34 to 65) 0.78 1.0 (1.0, 1.0) 1.0 (1.0, 1.0)
s-ICAM-1, ng/mL; median (IQR) 327 (242 to 367) 266 (240 to 323) 0.12 1.0 (1.0, 1.0) 1.0 (1.0, 1.0)
aAdjusted for age. *P <0.05. BP, blood pressure; CAC, coronary artery calcium; CRP, C-reactive protein; DAS28, disease activity score in 28 joints; HDL, high density
lipoprotein; IQR, interquartile range; IRR, incidence rate ratio; LDL, low density lipoprotein; MTX, methotrexate; RA, rheumatoid arthritis; s-ICAM, soluble intercellular
adhesion molecule.
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Table 5 Clinical Characteristics and the Risk of Progression of CAC (among those RA patients with Detectable CAC
at baseline)
Demographics B (95% CI) Adjusted Ba (95% CI)
Age, years −0.3 (−0.6, 1.3) NA
Male sex 8.3 (−8.1, 24.6) NA
Caucasian race; number (%) 28.0 (2.2, 53.7) NA
Education; number (%) −2.8 (−22.1, 16.5) −2.3 (−24.3, 19.7)
Some college or higher
Cardiovascular Risk Factors
Diabetes; number (%) −6.5 (−32.5, 19.5) 9.8 (−18.8, 38.4)
Hypertension (%) 13.1 (−2.3, 28.6) 5.4 (−14.6, 25.5)
Systolic BP, mm Hg −0.3 (−0.8, 0.2) −0.2 (−0.8, 0.4)
Diastolic BP, mm Hg 0.1 (−0.8, 1.0) 0.1 (−1.0, 1.2)
Dyslipidemia (%) 16.7 (−1.2, 34.6) 14.0 (−4.8, 32.8)
Total cholesterol, mg/dL −0.1 (−0.3, 0.1) −0.0 (−0.3, 0.2)
LDL cholesterol, mg/dL 0.0 (−0.3, 0.2) 0.1 (−0.3, 0.4)
HDL cholesterol, mg/dL −0.1 (−0.4, 0.4) 0.2 (−0.4, 0.9)
Triglycerides, mg/dL −0.03 (−0.1, 0.0) −0.1 (−0.2, 0.0)
Cigarette Smoking
Current; number (%) 19. 9 (−5.7, 45.5) 10.8 (−19.5, 41.2)
Serum inflammatory markers at baseline
CRP, mg/L; median (IQR) 3.2 (−3.5, 9.9) 4.4 (−3.0, 11.7)
IL-6, pg/mL; median (IQR) −1.8 (−11.4, 7.8) −0.8 (−11.4, 9.9)
Fibrinogen, mg/dL; median (IQR) 19.0 (−10.6, 48.5) 13.9 (−20.0, 47.8)
Disease characteristics at baseline
Disease duration (years) 0.4 (−0.4, 1.2) 0.6 (−0.28, 1.5)
RF 3.9 (−13.2, 21.0) 7.0 (−11.6, 25.6)
Anti-CCP 4.2 (−15.9, 24.4) −1.5 (−25.5, 22.5)
SE 2.2 (−16.2, 20.6) −6.8 (−27.8, 14.3)
DAS28 5.1 (−2.4, 12.7) 6.5 (−1.5, 14.5)
HAQ −5.1 (−17.6, 7.4) −0.8 (−16.5, 14.9)
Sharp score −0.0 (− 0.1, 0.1) −0.0 (−0.1, 0.1)
Current use of MTX −2.9 (−19.6, 13.7) −3.2 (−17.9, 23.2)
Current use of biologic agents 15.8 (−1.5, 33.0) 18.5 (−1.4, 38.4)
Current use of corticosteroids −8.6 (−25.8, 8.1) −5.3 (−26.1, 15.3)
Disease characteristics, expressed as average over follow-up
DAS28 2.0 (−7.6, 11.6) 4.8 (−6.0, 15.5)
CRP −3.9 (−11.2, 3.5) −1.1 (−9.7, 7.5)
IL-6 −5.4 (−13.6, 2.9) −6.0 (−16, 4.0)
Fibrinogen pg/mL; median (IQR) −7.3 (−45, 29) −6.1 (−50, 38)
aAdjusted for age, sex, race, hypertension, diabetes, smoking, dyslipidemia. BP, blood pressure; CAC, coronary artery calcium; CCP, cyclic citrullinated peptide; CRP,
C-reactive protein; DAS28, disease activity score in 28 joints; HAQ, Health Assessment Questionnaire; HDL, high density lipoprotein; IQR, interquartile range; IRR,
incidence rate ratio; LDL, low density lipoprotein; MTX, methotrexate; RA, rheumatoid arthritis; rheumatoid factor; RR, relative risk; SE, shared epitope.
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http://arthritis-research.com/content/15/5/R134and older age were significant predictors of incident
CAC over the period of follow-up, while inflamma-
tory and RA disease characteristics were not. Amongpatients with RA and CAC at baseline, no association
was found between traditional risk factors and CAC
progression.
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